Beyond BRCA: Exploring PARP Combinations in Prostate Cancer

Hear from the experts on how the latest clinical data from ASCO GU 2021 inform leveraging PARP inhibitor–based combinations for treating prostate cancer with and without DNA damage repair alterations. Review their insights in clinical commentaries along with slides, a podcast, and on-demand Webcast adapted from a live CCO Webinar.
Charles J. Ryan, MD
person default
Neal D. Shore, MD, FACS

Downloadable Slidesets

Download these slides from a live Webinar to gain expert insight on the rationale for combining PARP inhibitors and AR-directed therapy in mCRPC including the latest evidence from ASCO GU 2021.

person default Neal D. Shore, MD, FACS Released: February 19, 2021

This downloadable slide set from a live Webinar explores the rationale for combining PARP inhibitors with different types of agents for advanced prostate cancer, including immunotherapy, targeted agents, and radionuclides, incorporating the latest evidence from ASCO GU 2021.

Charles J. Ryan, MD Released: February 19, 2021

Download these slides from a live Webinar to review the most recent clinical data on single-agent PARP inhibitors in metastatic castration-resistant prostate cancer

Charles J. Ryan, MD Released: February 19, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue